New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
07:45 EDTMDSOMedidata Solutions price target raised to $55 from $47 at Stifel
Stifel increased its price target on Medidata as the firm thinks the company has a strong platform and robust analytics. The firm believes the company has a number of other positive catalysts and is well-positioned to deliver strong growth. Stifel expects the company to report favorable Q2 results and keeps a Buy rating on the shares.
News For MDSO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
11:15 EDTMDSOMedidata management to meet with Piper Jaffray
Group luncheon to be held in New York on November 25 hosted by Piper Jaffray.
08:37 EDTMDSOMedidata says results support methodology for risk-based monitoring
Subscribe for More Information
November 17, 2014
05:32 EDTMDSOMedidata announces collaboration with GlaxoSmithKline
Medidata (MDSO) announced the completion of a method development project conducted in partnership with GlaxoSmithKline (GSK) to evaluate the impact of unifying mobile health, or mHealth, devices with cloud-based technologies in a clinical trial setting. The joint initiative assessed the capabilities of mHealth tools and evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs. The collaborative project, which took place at GSK’s Human Performance Lab, demonstrated that mHealth technologies have the power to comprehensively collect large volumes of objective data that is reliable, secure and analysis-ready, and provides real-time, continuous insight into the well being of patients. All of the data collected was audited and is compliant with FDA regulations. Additionally, the effort indicated that mobile devices can support the long-term goal of lessening the burden on patients participating in studies by streamlining routine procedures, eliminating unnecessary ones and reducing visits to clinical trial sites.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use